FindTrial
Sign In

A clinical trial to study the effects and safety of 3 drugs in varied combinations, namely 1% Luliconazole cream plus 1% Ciclopirox Olamine cream, 1% Luliconazole cream plus 0.25% Amorolfine cream and 1% Luliconazole cream alone in the treatment of ringworm, a fungal infection of skin.

A single blinded, randomized controlled trial comparing the efficacy and safety of 1% Luliconazole cream plus 1% CiclopiroxOlamine cream, 1% Luliconazole cream plus 0.25% Amorolfine cream and 1% Luliconazole cream alone in the treatment of Tinea Corporis and Tinea cruris.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/12/048431
Enrollment
90
Registered
2022-12-23
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B354- Tinea corporis

Interventions

Intervention1: 1% Ciclopirox Olamine (CPO) cream and 1% Luliconazole cream: Patients randomly allocated to this arm will be treated as follows - 1% Ciclopirox Olamine (CPO) cream â?? to apply daily mo

Sponsors

SRM Medical College Hospital & Research Centre, SRMIST, Potheri
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of age 18years to 60 years, attending dermatology OPD of our hospital, and diagnosed to have Tinea corporis/cruris 2. Positive KOH mount test from skin scraping 3. Patients With mild to moderate extent of disease (less than 10% BSA involvement) and who are suitable for topical-only antifungal therapy.

Exclusion criteria

Exclusion criteria: 1.Patients with known allergy to azole antifungals, Amorolfine or Ciclopiroxolamine. 2.Pregnancy/ lactation 3.Patients with dermatophytosis affecting nails / scalp/ palms / soles 4.Patients with clinical features suggestive of secondary bacterial infections 5.Patients on immunosuppressive therapy 6.Patients who had used any topical medications for the tinea corporis/cruris lesions, in the last 2 weeks, or any systemic antifungal medications in the last 1 month. 7.Patients who are not willing to participate in the study.

Design outcomes

Primary

MeasureTime frame
1.To compare the scores of clinical parameters (Pruritus, erythema and scaling) and mycological status (KOH mount assessment) of combination of topical 1% Luliconazole cream and 1% ciclopiroxolamine cream, combination of topical 1% Luliconazole cream and 0.25% Amorolfine cream and 1% Luliconazole cream alone, in the treatment of Tinea corporis and Tinea crurisTimepoint: At end of 2nd week, 4th week and 6th week—

Secondary

MeasureTime frame
1.To compare the safety (based on evaluation for any adverse effects)of combination of topical 1% Luliconazole cream and 1% ciclopiroxolamine cream, combination of topical 1% Luliconazole cream and 0.25% Amorolfine cream and 1% Luliconazole cream alone, in the treatment of Tinea corporis and Tinea crurisTimepoint: At end of 2nd week, 4th week and 6th week—

Countries

India

Contacts

Public ContactRamachandran R

SRM Medical College Hospital & Research Centre, SRMIST

ramachar@srmist.edu.in9840458783

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026